164 related articles for article (PubMed ID: 34129945)
61. Assessment of extrafine beclomethasone/formoterol for the treatment of chronic obstructive pulmonary disease: A non-interventional study in a Bulgarian population.
Hodzhev VA; Kenderov AN; Ivanov YY; Gospodinova-Vulkova DP; Kalinov K
Pulm Pharmacol Ther; 2022 Dec; 77():102169. PubMed ID: 36252915
[TBL] [Abstract][Full Text] [Related]
62. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
[TBL] [Abstract][Full Text] [Related]
63. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
[TBL] [Abstract][Full Text] [Related]
64. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients.
Tzani P; Crisafulli E; Nicolini G; Aiello M; Chetta A; Clini EM; Olivieri D
Int J Chron Obstruct Pulmon Dis; 2011; 6():503-9. PubMed ID: 22069361
[TBL] [Abstract][Full Text] [Related]
65. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
66. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
67. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
[TBL] [Abstract][Full Text] [Related]
68. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M
Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340
[TBL] [Abstract][Full Text] [Related]
69. Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant.
Rony F; Cortellini M; Guasconi A; Mathews KS; Piccinno A; Poli G; Vanhoutte F; Klein J
Pulm Pharmacol Ther; 2024 Apr; 85():102299. PubMed ID: 38663512
[TBL] [Abstract][Full Text] [Related]
70. Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
Radovanovic D; Mantero M; Sferrazza Papa GF; Valenti V; Aliberti S; Di Marco F; Santus P
Expert Rev Respir Med; 2016 Oct; 10(10):1045-55. PubMed ID: 27552524
[TBL] [Abstract][Full Text] [Related]
71. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
[TBL] [Abstract][Full Text] [Related]
72. Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score.
Rogliani P; Ora J; Cavalli F; Cazzola M; Calzetta L
J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956108
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and Safety of Inhaled Glycopyrronium Bromide in COPD: A Randomized, Parallel Group, Dose-Ranging Study (GLIMMER).
Kerwin E; Feldman G; Pearle J; De La Cruz L; Edwards M; Beaudot C; Georges G
COPD; 2021 Apr; 18(2):181-190. PubMed ID: 33709856
[TBL] [Abstract][Full Text] [Related]
74. Effect of extrafine formulation of BDP/FF inhaler on asthma control, small airway function and airway inflammation among Mexican asthmatic patients. A retrospective analysis.
Díaz-García R; Flores-Ramírez G; Ramírez-Oseguera RT
Respir Med; 2020; 165():105932. PubMed ID: 32308205
[TBL] [Abstract][Full Text] [Related]
75. Glycopyrronium/Formoterol: A Review in COPD.
Al-Salama ZT; Frampton JE
Drugs; 2019 Sep; 79(13):1455-1466. PubMed ID: 31468315
[TBL] [Abstract][Full Text] [Related]
76. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
77. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
[TBL] [Abstract][Full Text] [Related]
78. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
[TBL] [Abstract][Full Text] [Related]
79. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
De Backer W; De Backer J; Verlinden I; Leemans G; Van Holsbeke C; Mignot B; Jenkins M; Griffis D; Ivanov S; Fitzpatrick J; St Rose E; Martin UJ; Reisner C
Ther Adv Respir Dis; 2020; 14():1753466620916990. PubMed ID: 32380894
[TBL] [Abstract][Full Text] [Related]
80. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
